Serum concentrations of metalloproteinase 2, metalloproteinase 9 and granzyme B in contact eczema patients.
INTRODUCTION: Contact eczema is a common skin condition with complex etiology, variable clinical presentation and lengthy therapy duration. The mechanism of contact eczema is complex, since it is affected by multiple inflammatory mediators. AIM: To assess concentrations of metalloproteinase 2 (MMP-2), metalloproteinase 9 (MMP-9) and granzyme B (GzmB) in patients with contact eczema. MATERIAL AND METHODS: Seventy patients with contact eczema and 30 healthy persons as controls were included in the study. In all subjects, MMP-2, MMP-9 and GzmB were determined using ELISA immunoassay. In study group patients, concentrations were assayed in periods of disease exacerbation and remission. Obtained results were analyzed statistically. RESULTS: Mean MMP-2 and GzmB concentrations were found to be significantly higher in the study group than in the control group. Mean MMP-2, MMP-9 and GzmB levels were also statistically significantly higher during skin lesion relapse compared to contact eczema remission periods. CONCLUSIONS: The presented paper demonstrates that MMP-2, MMP-9 and GzmB are good markers of contact eczema exacerbations.[1]References
- Serum concentrations of metalloproteinase 2, metalloproteinase 9 and granzyme B in contact eczema patients. Wojciechowska, M., Zbikowska-Gotz, M., Czajkowski, R., Bartuzi, Z. Postepy. Dermatol. Alergol (2013) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
